Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PRF Technologies Ltd. (PRFX) operates in the healthcare sector, focusing on specialty and generic drug manufacturing. The company is currently facing significant operational challenges, reflected in its negative gross and operating margins, which are indicative of high costs or inefficiencies in its production processes.
PRFX generates revenue primarily through the sale of generic and specialty pharmaceuticals. The company's competitive advantage lies in its ability to produce cost-effective generic drugs, although current operational inefficiencies are severely impacting profitability. The lack of debt provides some financial flexibility, but the negative margins indicate a need for operational restructuring.
Regulatory approvals for new drug formulations
Changes in pricing regulations for generics
Market share shifts in key therapeutic areas
Operational efficiency improvements
Regulatory changes impacting drug pricing and approval processes
Technological disruption in drug manufacturing processes
Intense competition from both established pharmaceutical companies and new entrants in the generic drug market
Potential for price erosion in generic drugs due to market saturation
Negative cash flow impacting liquidity
High operational costs leading to sustained losses
moderate - The healthcare sector is somewhat insulated from economic downturns, but demand for pharmaceuticals can be affected by consumer spending patterns.
Minimal impact as the company has no debt; however, rising rates could indirectly affect consumer spending on healthcare products.
minimal - The company has no debt, reducing its exposure to credit market fluctuations.
value - Investors may look for turnaround opportunities given the current low valuation metrics.
high - The stock has shown significant volatility, with a 1-year return of -79.0%.